Q-omics provides the consensus-scored ABHD17A profile across patient tissues and cancer cell-line models. ABHD17A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ABHD17A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ABHD17A RNA expression shows 18,151 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where ABHD17A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD17A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD17A survival associations across molecular data types. ABHD17A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD17A RNA expression–survival associations across cancer types. High ABHD17A expression shows unfavorable associations in ACC, LGG, KICH and PRAD, but favorable associations in UCEC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ABHD17A RNA expression.
This table summarizes ABHD17A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ABHD17A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD17A shows lower tumor expression in LUAD and higher tumor expression in KIRC, LIHC, COAD, KIRP and CHOL. The KIRC box plot shows higher ABHD17A RNA expression in tumor versus normal tissue (log2 FC = +0.817, t-test p < 0.001).
This table shows molecular features associated with ABHD17A in patient tissues and cancer cell lines. In patient samples, ABHD17A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD17A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
